testolactone has been researched along with flutamide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, KM; Cutler, GB; Hill, S; Jones, JV; Laue, L; Merke, DP | 1 |
| Cutler, GB; Merke, DP | 1 |
| Cutler, GB; Fields, J; Hill, S; Jones, JV; Keil, MF; Merke, DP | 1 |
| Calis, KA; Charmandari, E; Keil, MF; Merke, DP; Mohassel, MR; Remaley, A | 1 |
2 trial(s) available for testolactone and flutamide
| Article | Year |
|---|---|
A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Bone Development; Child; Child, Preschool; Dehydroepiandrosterone; Female; Flutamide; Humans; Hydrocortisone; Infant; Male; Seasons; Testolactone; Weight Gain | 1996 |
Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Bone Development; Child; Child, Preschool; Female; Flutamide; Follow-Up Studies; Growth; Hormones; Humans; Hydrocortisone; Male; Testolactone; Weight Gain | 2000 |
3 other study(ies) available for testolactone and flutamide
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
New approaches to the treatment of congenital adrenal hyperplasia.
Topics: Adrenal Hyperplasia, Congenital; Age Determination by Skeleton; Androgen Antagonists; Child; Cyproterone; Drug Therapy, Combination; Female; Fludrocortisone; Flutamide; Growth; Humans; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Spironolactone; Testolactone | 1997 |
Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Child; Cortisone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flutamide; Humans; Hydrocortisone; Male; Metabolism, Inborn Errors; Testolactone | 2002 |